{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:35:17Z","timestamp":1782776117176,"version":"3.54.5"},"reference-count":10,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,21]]},"DOI":"10.1182\/blood.2020008091","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T17:32:03Z","timestamp":1611250323000},"page":"289-291","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The balancing act in Burkitt lymphoma"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"first","affiliation":[{"name":"National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2021012116315743100_B1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2021012116315743100_B2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2021012116315743100_B3","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1200\/JCO.2007.11.0700","article-title":"Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin\u2019s lymphoma differ by non-Hodgkin\u2019s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report","volume":"25","author":"Salzburg","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021012116315743100_B4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3816\/CLM.2009.n.060","article-title":"Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens","volume":"9","author":"Kelly","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"2021012116315743100_B5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021012116315743100_B6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1182\/blood.V36.6.718.718","article-title":"Central nervous system involvement in Burkitt\u2019s lymphoma","volume":"36","author":"Ziegler","year":"1970","journal-title":"Blood"},{"issue":"8","key":"2021012116315743100_B7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"2021012116315743100_B8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"2021012116315743100_B9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","article-title":"Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study","volume":"93","author":"Neglia","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2021012116315743100_B10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/289\/1797682\/bloodbld2020008091c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/289\/1797682\/bloodbld2020008091c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T17:32:05Z","timestamp":1611250325000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/3\/289\/474935\/The-balancing-act-in-Burkitt-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008091","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}